TARA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Protara Therapeutics Inc (TARA) is not a strong buy for a beginner, long-term investor at this moment. Despite the company's potential market opportunities and analyst optimism, the technical indicators, options data, and recent news suggest caution. The stock's recent performance, mixed trial results, and lack of strong trading signals do not align with the user's investment goals.
The MACD is negative and expanding downward, RSI is neutral at 37.443, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 5.589), but there is no strong upward momentum.
Analyst coverage initiated with an Overweight rating and a $24 price target, highlighting three potentially substantial market opportunities. The ADVANCED-2 trial showed a 68.2% complete response rate with no Grade 3 or higher adverse events.
The stock dropped ~22% due to mixed trial results and a nearly 15% after-hours drop following the Phase 2 trial update. Technical indicators and options data do not show strong bullish sentiment. No significant hedge fund or insider trading activity.
In Q3 2025, revenue remained at $0 with no growth. Net income improved by 18.17% YoY but remains negative at -$13.26M. EPS decreased by 38% to -0.31, indicating continued financial struggles.
Piper Sandler initiated coverage with an Overweight rating and a $24 price target, citing unique market opportunities. However, no other recent analyst updates or revisions were noted.
